Regarding the latest clinical progress of D-2570, InventisBio stated that the Phase III clinical trial for psoriasis is proceeding as scheduled. D-2570 is currently under clinical development for various autoimmune diseases, including psoriasis, ulcerative colitis, psoriatic arthritis, and systemic lupus erythematosus (SLE). In December 2025, results from a Phase II clinical study of D-2570 in treating moderate-to-severe plaque psoriasis were published in the Journal of the American Academy of Dermatology (JAAD, IF: 11.79), a top-tier international journal in dermatology. Data showed that after 12 weeks of treatment, D-2570 exhibited excellent efficacy, significantly outperforming the placebo group across all efficacy endpoints. The results indicated significant improvements in the severity and extent of skin lesions after a short treatment period, demonstrating D-2570's ability to rapidly alleviate the disease burden for patients. Overall, D-2570 was well-tolerated, with most adverse events being mild to moderate and no serious adverse events (SAEs) reported. Its safety profile is consistent with other TYK2 inhibitors, with no new safety signals identified.
Regarding the latest progress of the KRAS G12C inhibitor Garsorasib (D-1553), the company noted that the 2025 CSCO Guidelines for Diagnosis and Treatment of Non-Small Cell Lung Cancer newly added Garsorasib as a Class I recommendation for late-line treatment of advanced NSCLC with KRAS G12C mutations. Currently, a randomized, controlled, double-blind, double-dummy, multicenter Phase III clinical study evaluating Garsorasib versus docetaxel in patients with KRAS G12C mutation-positive locally advanced or metastatic NSCLC who failed prior standard therapy is progressing smoothly. Garsorasib also demonstrated favorable anti-tumor efficacy and a manageable safety profile in patients with advanced pancreatic cancer harboring KRAS G12C mutations; these findings were published in the British Journal of Cancer (IF: 6.7) in December 2025.
Regarding the R&D progress of D-0502, the company stated that in December 2025, the combination therapy of D-0502 and JSKN016 (a bispecific antibody-drug conjugate [ADC] targeting TROP2/HER3 developed by Alphamab Oncology) received IND approval from China's National Medical Products Administration (NMPA). The proposed indication is for patients with locally advanced or metastatic HR-positive, HER2-negative (HR+/HER2-) breast cancer. This approval marks the official launch of the first clinical exploration of D-0502 in combination with an ADC, aiming to provide a new potential treatment option for HR+/HER2- advanced breast cancer patients whose disease progressed after endocrine combination therapies.

https://finance.eastmoney.com/a/202512313607182313.html